Curated News
By: NewsRamp Editorial Staff
October 12, 2026
Regentis Biomaterials Garners Surgeon Interest for GelrinC at ICRS Summit
TLDR
- Regentis Biomaterials gains surgeon interest for GelrinC, a 10-minute knee cartilage implant with Phase II KOOS scores 100 percent better than microfracture controls.
- GelrinC is a CE Mark-approved, cell-free hydrogel implant that erodes in the knee, enabling surrounding cells to regenerate cartilage in a controlled, synchronous process.
- Regentis Biomaterials advances GelrinC to restore knee cartilage, potentially improving quality of life for thousands awaiting an off-the-shelf treatment option.
- At the ICRS Summit in Porto, Regentis Biomaterials showcased GelrinC, a 10-minute hydrogel implant that regenerates knee cartilage and is advancing toward U.S. FDA pivotal trial.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in cartilage repair that could significantly improve outcomes for patients suffering from knee cartilage damage. With approximately 470,000 cases annually in the U.S. and no off-the-shelf treatment available, GelrinC's ability to regenerate durable, native-like cartilage in a single 10-minute procedure could address a major unmet need. Positive physician engagement and the ongoing FDA pivotal trial suggest that Regentis Biomaterials is moving closer to bringing this innovative solution to market, which could reduce pain, improve mobility, and delay or prevent the need for more invasive surgeries like knee replacement. For investors, the growing interest and clinical progress may signal a promising opportunity in the regenerative medicine space.
Summary
Regentis Biomaterials, a regenerative medicine company listed on the NYSE American under the ticker RGNT, has reported significant engagement from orthopedic surgeons and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society Summit in Porto, Portugal. The focus of discussions was GelrinC, the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure that takes approximately 10 minutes. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) compared with historical microfracture controls at two years, with MRI analyses showing durable, native-like cartilage regeneration. Regentis is now working to translate this physician interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. The company's Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.
The news was disseminated by InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials Garners Surgeon Interest for GelrinC at ICRS Summit
